Pharming Group N V 's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the fourth quarter 2025 to a ratio of 35.97, above the company average. This is a clear sign of healthy business climate in the Major Pharmaceutical Preparations industry and improving liquidity at their respective customers, during the fourth quarter 2025. Average receivable collection period, for the Pharming Group N V in Dec 31 2025 quarter, has decreased to 10 days, compared to 13 days, in the 0 quarter.

If we take a look into Healthcare sector 184 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Dec 31 2025 from 0 to 1571.

What is Receivable Turnover Ratio?
What is Pharming Group N V Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

PHAR Receivables Turnover Ratio	(Dec 31 2025) IV. Quarter	0 III. Quarter	0 II. Quarter	0 I. Quarter	(Dec 31 2024) IV. Quarter
Y / Y Receivable Change	0.57 %	-	-	-	17.29 %
Y / Y Revenue Change	26.56 %	-	-	-	21.09 %
Receivable Turnover Ratio (TTM)	35.97	28.59	28.59	28.59	28.59
PHAR's Total Ranking	# 1571	# 0	#	#	#
Accounts Receivable average collection period days	10	13	13	13	13
Seq. Receivable Change	-	-	-	-	-
Seq. Revenue Change	-	-	-	-	-

Receivable Turnover Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 44
Healthcare Sector	# 185
Overall Market	# 1571

Receivable Turnover Ratio Statistics
High	Average	Low
0.75	0.6	0.48
(Dec 31 2025)		(Dec 31 2022)

PHAR Company Profile • Back to PHAR Efficiency Comparisons • Compare PHAR Receivables Turnover Ratio to its Competitors

Financial Statements
Pharming Group N V 's Accounts Receivable	$ 42 Millions	Visit PHAR's Balance sheet
Pharming Group N V 's Sales TTM	$ 376 Millions	Visit PHAR's Income Statement
Sources of PHAR's Revenues		Visit PHAR's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
PHAR's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
PHAR's Growth Rates	PHAR's Roa	PHAR's Inventory Turnover Ratio	PHAR's Dividend Comparisons
PHAR's Profitability Ratios	PHAR's Roi	PHAR's Asset Turnover Ratio	PHAR's Dividend Growth
PHAR's Valuation Ratios	PHAR's Roe	PHAR's Financial Strength Ratios	PHAR's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Dec 31 2025, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Dec 31 2025	Receivable at quarter ending Dec 31 2025
Euda Health Holdings Limited	24.44	$ 5.993 Millions	$ 0.245 Millions
Longeveron Inc	22.20	$ 1.199 Millions	$ 0.054 Millions
Lifemd Inc	21.48	$ 193.686 Millions	$ 9.018 Millions
Fonar Corporation	21.42	$ 106.031 Millions	$ 4.950 Millions
Neuraxis Inc	21.11	$ 3.569 Millions	$ 0.169 Millions
Biorestorative Therapies Inc	20.88	$ 0.360 Millions	$ 0.017 Millions
Voyager Therapeutics Inc	19.59	$ 40.374 Millions	$ 2.061 Millions
Sonida Senior Living Inc	19.55	$ 381.141 Millions	$ 19.494 Millions
Siga Technologies Inc	19.47	$ 94.575 Millions	$ 4.856 Millions
Kiniksa Pharmaceuticals International Plc	19.45	$ 677.564 Millions	$ 34.828 Millions
Wave Life Sciences Ltd	18.34	$ 59.102 Millions	$ 3.223 Millions
Vystar Corporation	18.31	$ 0.055 Millions	$ 0.003 Millions
Arbutus Biopharma Corp	18.10	$ 14.083 Millions	$ 0.778 Millions
Scinai Immunotherapeutics Ltd	17.96	$ 1.311 Millions	$ 0.073 Millions
Nurix Therapeutics Inc	17.68	$ 83.980 Millions	$ 4.750 Millions
Bioharvest Sciences Inc	17.42	$ 34.508 Millions	$ 1.981 Millions
Cue Biopharma Inc	16.99	$ 27.466 Millions	$ 1.616 Millions
Bioage Labs Inc	16.01	$ 8.995 Millions	$ 0.562 Millions
Nutriband Inc	15.64	$ 2.037 Millions	$ 0.130 Millions
China Pharma Holdings Inc	15.58	$ 4.144 Millions	$ 0.266 Millions
Talkspace Inc	15.35	$ 228.871 Millions	$ 14.915 Millions
Vaxart Inc	15.05	$ 237.258 Millions	$ 15.765 Millions
Precipio inc	15.02	$ 24.049 Millions	$ 1.601 Millions
Innoviva Inc	14.98	$ 384.667 Millions	$ 25.683 Millions
Nanobiotix S a	14.70	$ 36.850 Millions	$ 2.507 Millions
Silence Therapeutics Plc	14.52	$ 0.559 Millions	$ 0.039 Millions
Qhslab Inc	14.47	$ 2.692 Millions	$ 0.186 Millions
Sutro Biopharma Inc	13.92	$ 102.484 Millions	$ 7.365 Millions
Amneal Pharmaceuticals Inc	13.44	$ 3,018.308 Millions	$ 224.629 Millions
10x Genomics Inc	13.28	$ 641.881 Millions	$ 48.330 Millions

Date modified: 2026-07-07T12:47:48+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.